phrykt

Iovance Biotherapeutics, Inc. (IOVA): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of IOVA were reported in the last 12 months. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Iovance Biotherapeutics

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IOVA

291 funds and institutions reported IOVA shares worth $1.2B at the end of Q2 2026, about 65% of the company. The largest holder is BlackRock, Inc. with 8.3%.

Funds and institutions (13F) 65%Everyone else 35%

10 largest owners, by share of the company

BlackRock, Inc.8.3%
Mhr Fund Management LLC6.5%
State Street Corp5.5%
Two Sigma Investments, LP4.3%
Vanguard Capital Management LLC4.1%
Vanguard Portfolio Management LLC3.2%
Geode Capital Management, LLC2.3%
Millennium Management LLC1.9%
Dimensional Fund Advisors LP1.4%
Palo Alto Investors LP1.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.36.96M8.28%$154M+19%
Mhr Fund Management LLC28.97M6.49%$121MNo change
State Street Corp24.48M5.48%$102M+40%
Two Sigma Investments, LP19.01M4.26%$79.1M+39%
Vanguard Capital Management LLC18.20M4.08%$75.7M+10%
Vanguard Portfolio Management LLC14.39M3.22%$59.9M+23%
Geode Capital Management, LLC10.32M2.31%$43M+20%
Millennium Management LLC8.53M1.91%$35.5M-9%
Dimensional Fund Advisors LP6.46M1.45%$26.9M+144%
Palo Alto Investors LP5.30M1.19%$22M-17%
Goldman Sachs Group Inc5.10M1.14%$21.2M-42%
Nuveen, LLC5.00M1.12%$20.8M+36%
Bank of America Corp4.99M1.12%$20.8M-41%
Morgan Stanley4.99M1.12%$20.7M-20%
Jupiter Asset Management Ltd4.54M1.02%$18.9M–
Jane Street Group, LLC4.39M0.98%$18.3M+5%
Northern Trust Corp4.15M0.93%$17.3M+44%
AQR Capital Management LLC3.87M0.87%$16.1M+520%
Wells Fargo & Company3.25M0.73%$13.5M+57%
Charles Schwab Investment Management Inc3.22M0.72%$13.4M+16%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No IOVA insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IOVA short interest

High short interest. 14.1% of IOVA shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went down 39%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 65.19M IOVA shares were sold short, 14.1% of the shares outstanding, up 10.6% from the report before. At the average daily volume of 15.64M shares, buying them all back would take about 4.2 trading days (days to cover).

Shares short, % of all shares

14.1%May 15Oct 3025.5%

Days to cover

4.2May 15Oct 309.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202665.19M14.09%+11%15.64M4.2
Oct 15, 202658.93M13.01%-9%13.31M4.4
Sep 30, 202664.83M14.31%-26%22.91M2.8
Sep 15, 202687.13M19.23%-1%11.73M7.4
Aug 31, 202688.14M19.46%-14%16.70M5.3
Aug 14, 2026102.94M22.73%+3%21.51M4.8
Jul 31, 202699.98M22.07%+0%15.92M6.3
Jul 15, 202699.89M22.37%-1%16.90M5.9
Jun 30, 2026100.53M22.51%-3%14.16M7.1
Jun 15, 2026103.49M23.18%-1%13.11M7.9
May 29, 2026104.25M23.35%-2%12.72M8.2
May 15, 2026106.61M23.88%-7%17.78M6.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Iovance Biotherapeutics company events

Iovance Biotherapeutics filed 13 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AnnouncementIovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. Filing
  2. Nov 5, 2026ResultsReleased financial results. Filing
  3. Oct 29, 2026AnnouncementIovance Biotherapeutics, Inc. issued a press release announcing updated results from Cohorts 1 and 2 of the Company’s Phase 2 IOV-LUN-202 trial and a biomarker-enriched precision tumor infiltrating lymphocyte strategy for lifileucel in previously treated non-squamous metastatic non-small-cell lung… Filing
  4. Oct 5, 2026AnnouncementIovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. Filing
  5. Sep 29, 2026AnnouncementIovance Biotherapeutics, Inc. issued a press release updating its full year 2026 revenue guidance. Filing
  6. Aug 6, 2026AnnouncementIovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. Filing
  7. Aug 6, 2026ResultsReleased financial results. Filing
  8. Jul 2, 2026AnnouncementIovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. Filing
  9. Jun 10, 2026AnnouncementThe Company received marketing authorization from the Therapeutic Goods Administration of Australia for Amtagvi® for previously treated advanced (metastatic or unresectable) melanoma. Filing
  10. May 7, 2026ResultsReleased financial results. Filing
  11. Mar 20, 2026LeadershipWendy Yarno, a member of the Board of Directors of Iovance Biotherapeutics, Inc., provided notice to the Board that she will retire from the Board and not be standing for re-election at the Company’s annual meeting of stockholders currently anticipated to be held in June 2026. Filing
  12. Feb 24, 2026AnnouncementThe Company updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. Filing
  13. Jan 9, 2026AnnouncementIovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Iovance Biotherapeutics financials

Famous investors that hold IOVA

5 of the 50 well-known investors we track reported holding IOVA in their latest 13F filing. The largest position is Israel Englander's, worth $27.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20261.87M$27.7M0.0%-78%
Ken Griffin · Citadel AdvisorsQ3 20261.17M$17.4M0.0%-44%
Steve Cohen · Point72 Asset ManagementQ3 20261.02M$15.1M0.0%New
Ray Dalio · Bridgewater AssociatesQ3 2026521,546$7.7M0.0%New
Jim Simons · Renaissance TechnologiesQ3 2026257,700$3.8M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IOVA in the last 120 days.

FiledHolderFormStake
Nov 10, 2026STATE STREET CORPORATION13G4.8%
Nov 10, 2026STATE STREET CORPORATION13G4.8%

Questions about Iovance Biotherapeutics, Inc. (IOVA) stock

Who owns the most IOVA stock?

The largest reported owner of Iovance Biotherapeutics, Inc. (IOVA) is BlackRock, Inc., with 8.3% of the company. In total, 291 funds and institutions reported holding IOVA at the end of Q2 2026, together about 65% of the shares. See the largest owners.

Are IOVA insiders buying or selling?

No IOVA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in IOVA?

As of Oct 30, 2026, 65.19M IOVA shares were sold short, 14.1% of the shares outstanding, up 10.6% from the report before. At the average daily volume of 15.64M shares, buying them all back would take about 4.2 trading days (days to cover). See the history.

Which famous investors hold IOVA?

5 of the 50 well-known investors we track reported IOVA in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $27.7M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.